Merit Medical Systems reported second-quarter 2026 revenue of $418.8 million, up 9.5% year over year and 3.5% above the Zacks Consensus Estimate, while adjusted earnings of $1.19 per share rose 18% and beat consensus by 23.9%. Organic revenue grew 9% at constant currency, with U.S. revenue up 11.5% and international revenue up 4.7%. Therapeutic revenue increased 15% on a reported basis, led by 24% growth in Cardiac Therapies and 29% growth in Endoscopy. Adjusted gross margin expanded 260 basis points to 55.8%, but excluding tariff refunds it was 54.2%, up 98 basis points, and management expects about $16 million of tariff costs in 2026. The company raised its 2026 adjusted earnings guidance to $4.25 to $4.35 per share from $4.01 to $4.15 and lifted its revenue range to $1.631 billion to $1.643 billion. MMSI trades at 20.3 times forward earnings versus 17.6 times for its Zacks sub-industry, and carries a Zacks Rank of 3, or Hold.
Merit Medical Systems IncQ2 revenue and EPS beat estimates, guidance raised
Boston Scientific Corp
Medtronic PLC